GlobeNewsWire
14 Jun 2026, 07:15 UTC · 3h ago
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.






